

REMARKS/ARGUMENTS

Preliminarily, Applicants respectfully thank the Examiner for allowing claims 21-22 and indicating the allowability of claims 5-6, and 24-25.

Similarly, with respect to claims 16 and 23, applicants believe that the amendments to these claims have placed them in form for allowance.

Upon entry of this amendment, claims 1-52 are pending, with claims 1, 21, 23, 30 , 33, and 36 being independent. Claims 30-52 have been added. Support for these claims can be found throughout the specification.

Claims 1-4, 7-9, 12-20, 23, and 26-29 have been rejected under 35 U.S.C. § 103(a) as being unpatentable in view of U.S. Patent No. 6,136,880 to Snowwhite *et al.* Claims 1-4, 8-9, 12-16 and 19-20 have been rejected under 35 U.S.C. § 103(a) as being unpatentable in view of U.S. Patent No. 6,359,025 to Snowwhite *et al.* Claims 1, 3-4, 8-9 , 13-17, and 18-20 have been rejected under 35 U.S.C. § 103(a) as being unpatentable over U.S. Patent No. 6,057,034 to Yamakazi *et al.* Claims 1, 3, 8 and 10-20 have been rejected under 35 U.S.C. § 103(a) as being unpatentable over U.S. Patent No. 4,782,129 to Moschovis *et al.*

Assuming *arguendo* that a *prima facie* case of obviousness is presented by the cited references, none of these references teaches or suggests the unexpected results presented in Tables 7 and 8, specifically examples 10 and 12 and comparative examples D and E. Excerpts of these tables are presented below for convenience.

Table 7 Excerpt

Components	Comp. Ex. D	Ex. 10
Oligomer 7 (wt. %)	56.00	56.00
Propoxylated nonyl phenol acrylate (wt. %)	36.50	38.00
Irgacure 184 (wt. %)	6.00	2.00
Irgacure 1700 (wt.%)	--	--
Lucirin TPO (wt. %)	--	0.50
Darocur 1173 (wt. %)	--	2.00
Irganox 1035 (wt. %)	1.00	1.00
A-189 (wt. %)	0.49	0.49
A-1110 (wt. %)	0.01	0.01
% RAU (4.4 mJ/cm ²)	58.3	67.9

Table 8 Excerpt

Components	Comp. Ex. E	Ex. 12
Oligomer 8	35.00	35.00
Oligomer 9	35.00	35.00
Hexane diol diacrylate	24.995	25.995
Irgacure 184 (wt.%)	4.00	1.00
Lucirin TPO (wt. %)	--	0.70
Irgacure 819 (wt. %)	--	0.3
Darocur 1173 (wt. %)	--	1.00
Irganox 1035 (wt. %)	1.00	1.00
DC 57 (wt. %)	0.005	0.005
% RAU (4.4 mJ/cm ²)	50.9	66.8

These examples show the unexpected results that a lower total amount by wt% of three photoinitiators in a radiation-curable composition gives significantly greater cure speeds as evidenced by % RAU, than a substantially identical composition with a higher wt% of a single photoinitiator. For at least these reasons, the claims are patentable over the cited references.

Therefore, as all objections and rejections having been addressed and overcome, it is respectfully submitted that the present application is in a condition for allowance and a Notice to that effect is earnestly solicited.

Should any issues remain unresolved, the Examiner is encouraged to contact the undersigned attorney for Applicants at the telephone number indicated below in order to expeditiously resolve any remaining issues.

Please charge any fees associated with the submission of this paper to counsel's Deposit Account Number 503-121. The Commissioner for Patents is also authorized to credit any over payments to the above-referenced Deposit Account.

Respectfully submitted,

MAYER BROWN ROWE & MAW

By:



Paul L. Sharer
Registration No. 36,004
Direct No. (202) 263-3340

Mayer, Brown, Rowe & Maw LLP
Intellectual Property Group
1909 K Street, N.W.
Washington, D.C. 20006-1101
Customer No.: 000043569